ER, PR, and HER2, routinely available in breast cancer specimens, are reliable, inexpensive, and useful for therapeutic decision making, and the results of these tests are recorded in cancer registries allowing for population-based research which make them a reasonable substitute for the more expensive molecular subtyping [8, 9]. This evidence concerns the gene PGR and breast cancer.